VanEck Biotech ETF gets a Hold rating as top holdings face low growth, patent cliffs, and rich valuation vs. peers. Click to read my latest analysis of BBH.

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. Products that are ...

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based ...

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of AUM) IVW: $11.0 million (8.6% of AUM) ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...